Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2022-05-26 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 26, 2022. It announces the commencement of dosing in a Phase 1a clinical study and includes a press release as an exhibit. The text explicitly states that the information is being furnished and shall not be "filed" for the purpose of the Exchange Act, indicating this is a regulatory announcement rather than a full financial or operational report. The document length is 3593 characters, which is relatively short and consistent with a regulatory announcement rather than a detailed report. There are no financial statements or detailed financial data included. Therefore, this document fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2022-05-26 English
FORM 8-K
Investor Presentation Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 20, 2022. It specifically states in Item 7.01 that the company is using an attached presentation for investor meetings, identified as Exhibit 99.1, described as an 'Investor Presentation dated May 20, 2022.' The text clarifies that this presentation is being furnished and not filed for regulatory purposes, indicating the document's primary content is an investor presentation. The document length is 3423 characters, which is relatively short and consistent with a Form 8-K filing that includes an investor presentation. There is no detailed financial data or comprehensive report content, so it is not an Annual Report, Interim Report, or Earnings Release. The presence of an investor presentation as the main exhibit and the description in the text supports classification as an Investor Presentation (IP).
2022-05-20 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the quarter ended March 31, 2022. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 3169 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, initial announcements of quarterly financial results in a press release format correspond to an Earnings Release (ER). Therefore, this document should be classified as an Earnings Release (ER).
2022-05-12 English
FORM 10-Q
Interim / Quarterly Report Q1 2022
2022-05-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 10, 2022. It announces a press release regarding regulatory approval from the MHRA for a clinical study protocol amendment. The document is short (3,794 characters) and primarily serves to disclose this event and attach the press release as Exhibit 99.1. There are no financial statements or detailed financial data included. The content is an announcement of a material event rather than a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-05-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 5, 2022. It announces a regulatory development regarding clinical trial approval in Poland and includes a press release as an exhibit. The text explicitly states that the information is being furnished and shall not be "filed" for the purpose of the Exchange Act, indicating this is an announcement rather than a full report. The document length is 3795 characters, which is relatively short and consistent with a regulatory announcement rather than a detailed financial or management report. There are no financial statements or substantive financial data included. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-05-05 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.